First line combination therapy improves progression-free survival in advanced lung cancer

A new combination therapy for the first line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of the phase III IMpower150 trial presented at the ESMO Immuno Oncology Congress 2017. …read more

Source: EurekAlert

(Visited 4 times, 1 visits today)

Popular Posts